Baidu
map

肿瘤科指南

订阅

MedSci主页 / 所有栏目 / 肿瘤科指南

2018 AGO建议：早期乳腺癌患者的诊断和治疗（更新版）

2018-07-13 德国妇科肿瘤小组 Breast Care (Basel). 2018 Jul;13(3):196-208.

早期乳腺癌患

2018年7月，德国妇科肿瘤小组(AGO)发布了早期乳腺癌患者的诊断和治疗更新版，将近20年来，德国妇科肿瘤小组(AGO)一直在准备以及更新关于早期和转移性乳腺癌的诊断和治疗建议，2018跟新版早期乳腺癌诊断和治疗建议的主要内容涉及乳腺癌一级预防，风险评估和预防，乳腺癌的诊断，病理临床治疗等。

中文标题：

2018 AGO建议：早期乳腺癌患者的诊断和治疗（更新版）

英文标题：

AGO Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2018.

发布机构：

德国妇科肿瘤小组

发布日期：

2018-07-13

简要介绍：

2018年7月，德国妇科肿瘤小组(AGO)发布了早期乳腺癌患者的诊断和治疗更新版，将近20年来，德国妇科肿瘤小组(AGO)一直在准备以及更新关于早期和转移性乳腺癌的诊断和治疗建议，2018跟新版早期乳腺癌诊断和治疗建议的主要内容涉及乳腺癌一级预防，风险评估和预防，乳腺癌的诊断，病理临床治疗等。 

拓展指南：与乳腺癌相关指南：

相关资料下载：
[AttachmentFileName(sort=100, fileName=2018 AGO建议：早期乳腺癌患者的诊断和治疗（更新版）)] GetToolGuiderByIdResponse(projectId=1, id=ff75b1c001626a66, title=2018 AGO建议：早期乳腺癌患者的诊断和治疗（更新版）, enTitle=AGO Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2018., guiderFrom=Breast Care (Basel). 2018 Jul;13(3):196-208., authorId=null, author=, summary=2018年7月，德国妇科肿瘤小组(AGO)发布了早期乳腺癌患者的诊断和治疗更新版，将近20年来，德国妇科肿瘤小组(AGO)一直在准备以及更新关于早期和转移性乳腺癌的诊断和治疗建议，2018跟新版早期乳腺癌诊断和治疗建议的主要内容涉及乳腺癌一级预防，风险评估和预防，乳腺癌的诊断，病理临床治疗等。 , cover=, journalId=null, articlesId=null, associationId=1692, associationName=德国妇科肿瘤小组, associationIntro=, copyright=0, guiderPublishedTime=Fri Jul 13 00:00:00 CST 2018, originalUrl=, linkOutUrl=, content=<div>2018年7月，德国妇科肿瘤小组(AGO)发布了早期乳腺癌患者的诊断和治疗更新版，将近20年来，德国妇科肿瘤小组(AGO)一直在准备以及更新关于早期和转移性乳腺癌的诊断和治疗建议，2018跟新版早期乳腺癌诊断和治疗建议的主要内容涉及乳腺癌一级预防，风险评估和预防，乳腺癌的诊断，病理临床治疗等。 </div> <div><br> </div>拓展指南：<strong>与<font color=red>乳腺癌</font>相关指南：</strong><br><ul><li><a href="//www.sandwebs.com/guideline/show_article.do?id=6290a1c001625122" title="2018 AGO建议：晚期和转移性乳腺癌的诊断和治疗（更新版）" target=_blank>2018 AGO建议：晚期和转移性乳腺癌的诊断和治疗（更新版）</a></li> <li><a href="//www.sandwebs.com/guideline/show_article.do?id=69b911c00162283a" title="NCCN临床实践指南：遗传/家族高风险评估-乳腺癌和卵巢癌（2019.V2）" target=_blank>NCCN临床实践指南：遗传/家族高风险评估-乳腺癌和卵巢癌（2019.V2）</a></li> <li><a href="//www.sandwebs.com/guideline/show_article.do?id=fc5231c00161526e" title="NCCN临床实践指南：遗传/家族高风险评估-乳腺癌和卵巢癌（2019.V1）" target=_blank>NCCN临床实践指南：遗传/家族高风险评估-乳腺癌和卵巢癌（2019.V1）</a></li> <li><a href="//www.sandwebs.com/guideline/show_article.do?id=aa95b1c00160e84d" title="2018 香港乳腺癌预防和筛查建议" target=_blank>2018 香港乳腺癌预防和筛查建议</a></li> <li><a href="//www.sandwebs.com/guideline/show_article.do?id=356a41c001606ead" title="2018 CAP临床实践指南：乳腺癌HER2检测" target=_blank>2018 CAP临床实践指南：乳腺癌HER2检测</a></li> 更多信息请点击：<a href="//www.sandwebs.com/guideline/list.do?q=%E4%B9%B3%E8%85%BA%E7%99%8C" target=_blank>有关乳腺癌更多指南</a></ul>, tagList=[TagDto(tagId=79036, tagName=早期乳腺癌患)], categoryList=[CategoryDto(categoryId=5, categoryName=肿瘤科, tenant=100), CategoryDto(categoryId=89, categoryName=乳腺癌, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=null, articleKeyword=null, articleKeywordNum=null, guiderKeywordId=null, guiderKeyword=null, guiderKeywordNum=null, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=其他, guiderLanguage=0, guiderRegion=0, opened=0, paymentType=null, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=8804, appHits=540, showAppHits=0, pcHits=7067, showPcHits=1833, likes=272, shares=11, comments=5, approvalStatus=1, publishedTime=Sat Aug 11 23:12:31 CST 2018, publishedTimeString=2018-07-13, pcVisible=1, appVisible=1, editorId=2020535, editor=qiushida2, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=1, createdBy=null, createdName=qiushida2, createdTime=Sat Aug 11 23:12:31 CST 2018, updatedBy=null, updatedName=null, updatedTime=Sat Jan 06 16:52:14 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=100, fileName=2018 AGO建议：早期乳腺癌患者的诊断和治疗（更新版）)])
2018 AGO建议：早期乳腺癌患者的诊断和治疗（更新版）
下载请点击：
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=338305, encodeId=2cbf338305dd, content=早期乳腺癌的诊断和治疗。, beContent=null, objectType=guider, channel=null, level=null, likeNumber=123, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/07/16/3b24606172648eea459125cb74754afe.jpg, createdBy=6c022216608, createdName=liumin1987, createdTime=Mon Aug 13 08:58:00 CST 2018, time=2018-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=338075, encodeId=d4be3380e51d, content=学习了！！！！！！, beContent=null, objectType=guider, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59321624668, createdName=zb1235672, createdTime=Sun Aug 12 07:19:59 CST 2018, time=2018-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=338067, encodeId=5b1c33806ea0, content=阅, beContent=null, objectType=guider, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/fhZdOu27e88Voqh19n8eF8cLplo8L4nicKtH0WnE3KFELXns5XDu8rsiceK2HHDZc2SEStia5VV3Pia2QLMVqlWbHw/0, createdBy=6e012139475, createdName=神功盖世, createdTime=Sun Aug 12 06:51:40 CST 2018, time=2018-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=338012, encodeId=695d33801244, content=学习了，谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1bb241978, createdName=phoebeyan520, createdTime=Sun Aug 12 00:29:34 CST 2018, time=2018-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=337997, encodeId=388233e997a0, content=学习了，谢谢分享。, beContent=null, objectType=guider, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/xkvRjYnJzzRJ2R0y7VhicibvkjPWHjIMmu4ZpKnE9cWAu4lVicS3uDUCfF4M4JWvrkrYfpb2KehPV0Ee29tPqyPEebBUibiaKhnvD/0, createdBy=f8412001184, createdName=惠映实验室, createdTime=Sat Aug 11 23:39:36 CST 2018, time=2018-08-11, status=1, ipAttribution=)]
    2018-08-13 liumin1987

    早期乳腺癌的诊断和治疗。

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=338305, encodeId=2cbf338305dd, content=早期乳腺癌的诊断和治疗。, beContent=null, objectType=guider, channel=null, level=null, likeNumber=123, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/07/16/3b24606172648eea459125cb74754afe.jpg, createdBy=6c022216608, createdName=liumin1987, createdTime=Mon Aug 13 08:58:00 CST 2018, time=2018-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=338075, encodeId=d4be3380e51d, content=学习了！！！！！！, beContent=null, objectType=guider, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59321624668, createdName=zb1235672, createdTime=Sun Aug 12 07:19:59 CST 2018, time=2018-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=338067, encodeId=5b1c33806ea0, content=阅, beContent=null, objectType=guider, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/fhZdOu27e88Voqh19n8eF8cLplo8L4nicKtH0WnE3KFELXns5XDu8rsiceK2HHDZc2SEStia5VV3Pia2QLMVqlWbHw/0, createdBy=6e012139475, createdName=神功盖世, createdTime=Sun Aug 12 06:51:40 CST 2018, time=2018-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=338012, encodeId=695d33801244, content=学习了，谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1bb241978, createdName=phoebeyan520, createdTime=Sun Aug 12 00:29:34 CST 2018, time=2018-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=337997, encodeId=388233e997a0, content=学习了，谢谢分享。, beContent=null, objectType=guider, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/xkvRjYnJzzRJ2R0y7VhicibvkjPWHjIMmu4ZpKnE9cWAu4lVicS3uDUCfF4M4JWvrkrYfpb2KehPV0Ee29tPqyPEebBUibiaKhnvD/0, createdBy=f8412001184, createdName=惠映实验室, createdTime=Sat Aug 11 23:39:36 CST 2018, time=2018-08-11, status=1, ipAttribution=)]
    2018-08-12 zb1235672

    学习了！！！！！！

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=338305, encodeId=2cbf338305dd, content=早期乳腺癌的诊断和治疗。, beContent=null, objectType=guider, channel=null, level=null, likeNumber=123, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/07/16/3b24606172648eea459125cb74754afe.jpg, createdBy=6c022216608, createdName=liumin1987, createdTime=Mon Aug 13 08:58:00 CST 2018, time=2018-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=338075, encodeId=d4be3380e51d, content=学习了！！！！！！, beContent=null, objectType=guider, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59321624668, createdName=zb1235672, createdTime=Sun Aug 12 07:19:59 CST 2018, time=2018-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=338067, encodeId=5b1c33806ea0, content=阅, beContent=null, objectType=guider, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/fhZdOu27e88Voqh19n8eF8cLplo8L4nicKtH0WnE3KFELXns5XDu8rsiceK2HHDZc2SEStia5VV3Pia2QLMVqlWbHw/0, createdBy=6e012139475, createdName=神功盖世, createdTime=Sun Aug 12 06:51:40 CST 2018, time=2018-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=338012, encodeId=695d33801244, content=学习了，谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1bb241978, createdName=phoebeyan520, createdTime=Sun Aug 12 00:29:34 CST 2018, time=2018-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=337997, encodeId=388233e997a0, content=学习了，谢谢分享。, beContent=null, objectType=guider, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/xkvRjYnJzzRJ2R0y7VhicibvkjPWHjIMmu4ZpKnE9cWAu4lVicS3uDUCfF4M4JWvrkrYfpb2KehPV0Ee29tPqyPEebBUibiaKhnvD/0, createdBy=f8412001184, createdName=惠映实验室, createdTime=Sat Aug 11 23:39:36 CST 2018, time=2018-08-11, status=1, ipAttribution=)]
    2018-08-12 神功盖世

    阅

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=338305, encodeId=2cbf338305dd, content=早期乳腺癌的诊断和治疗。, beContent=null, objectType=guider, channel=null, level=null, likeNumber=123, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/07/16/3b24606172648eea459125cb74754afe.jpg, createdBy=6c022216608, createdName=liumin1987, createdTime=Mon Aug 13 08:58:00 CST 2018, time=2018-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=338075, encodeId=d4be3380e51d, content=学习了！！！！！！, beContent=null, objectType=guider, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59321624668, createdName=zb1235672, createdTime=Sun Aug 12 07:19:59 CST 2018, time=2018-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=338067, encodeId=5b1c33806ea0, content=阅, beContent=null, objectType=guider, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/fhZdOu27e88Voqh19n8eF8cLplo8L4nicKtH0WnE3KFELXns5XDu8rsiceK2HHDZc2SEStia5VV3Pia2QLMVqlWbHw/0, createdBy=6e012139475, createdName=神功盖世, createdTime=Sun Aug 12 06:51:40 CST 2018, time=2018-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=338012, encodeId=695d33801244, content=学习了，谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1bb241978, createdName=phoebeyan520, createdTime=Sun Aug 12 00:29:34 CST 2018, time=2018-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=337997, encodeId=388233e997a0, content=学习了，谢谢分享。, beContent=null, objectType=guider, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/xkvRjYnJzzRJ2R0y7VhicibvkjPWHjIMmu4ZpKnE9cWAu4lVicS3uDUCfF4M4JWvrkrYfpb2KehPV0Ee29tPqyPEebBUibiaKhnvD/0, createdBy=f8412001184, createdName=惠映实验室, createdTime=Sat Aug 11 23:39:36 CST 2018, time=2018-08-11, status=1, ipAttribution=)]
    2018-08-12 phoebeyan520

    学习了，谢谢分享

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=338305, encodeId=2cbf338305dd, content=早期乳腺癌的诊断和治疗。, beContent=null, objectType=guider, channel=null, level=null, likeNumber=123, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/07/16/3b24606172648eea459125cb74754afe.jpg, createdBy=6c022216608, createdName=liumin1987, createdTime=Mon Aug 13 08:58:00 CST 2018, time=2018-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=338075, encodeId=d4be3380e51d, content=学习了！！！！！！, beContent=null, objectType=guider, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59321624668, createdName=zb1235672, createdTime=Sun Aug 12 07:19:59 CST 2018, time=2018-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=338067, encodeId=5b1c33806ea0, content=阅, beContent=null, objectType=guider, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/fhZdOu27e88Voqh19n8eF8cLplo8L4nicKtH0WnE3KFELXns5XDu8rsiceK2HHDZc2SEStia5VV3Pia2QLMVqlWbHw/0, createdBy=6e012139475, createdName=神功盖世, createdTime=Sun Aug 12 06:51:40 CST 2018, time=2018-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=338012, encodeId=695d33801244, content=学习了，谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1bb241978, createdName=phoebeyan520, createdTime=Sun Aug 12 00:29:34 CST 2018, time=2018-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=337997, encodeId=388233e997a0, content=学习了，谢谢分享。, beContent=null, objectType=guider, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/xkvRjYnJzzRJ2R0y7VhicibvkjPWHjIMmu4ZpKnE9cWAu4lVicS3uDUCfF4M4JWvrkrYfpb2KehPV0Ee29tPqyPEebBUibiaKhnvD/0, createdBy=f8412001184, createdName=惠映实验室, createdTime=Sat Aug 11 23:39:36 CST 2018, time=2018-08-11, status=1, ipAttribution=)]
    2018-08-11 惠映实验室

    学习了，谢谢分享。

    0

Baidu
map
Baidu
map
Baidu
map